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Evaluation of Weight Change During Carboplatin Therapy in Dogs
With Appendicular Osteosarcoma
A.L. Story , S.E. Boston, J.J. Kilkenny, A. Singh, J.P. Woods, W.T.N. Culp, K.A. Skorupski,
and X. Lu
Background: The prevalence of cancer cachexia in veterinary medicine has not been studied widely, and as of yet, no
definitive diagnostic criteria effectively assess this syndrome in veterinary patients.
Objectives: (1) To determine the patterns of weight change in dogs with appendicular osteosarcoma treated with amputa-
tion and single-agent carboplatin during the course of adjuvant chemotherapy; and (2) to determine whether postoperative
weight change is a negative prognostic indicator for survival time in dogs with osteosarcoma.
Animals: Eighty-eight dogs diagnosed with appendicular osteosarcoma. Animals were accrued from 3 veterinary teaching
hospitals.
Methods: Retrospective, multi-institutional study. Dogs diagnosed with appendicular osteosarcoma and treated with limb
amputation followed by a minimum of 4 doses of single-agent carboplatin were included. Data analyzed in each patient
included signalment, tumor site, preoperative serum alkaline phosphatase activity (ALP), and body weight (kg) at each carbo-
platin treatment.
Results: A slight increase in weight occurred over the course of chemotherapy, but this change was not statistically signifi-
cant. Weight change did not have a significant effect on survival. Institution, patient sex, and serum ALP activity did not
have a significant effect on survival.
Conclusions and Clinical Importance: Weight change was not a prognostic factor in these dogs, and weight loss alone may
not be a suitable method of determining cancer cachexia in dogs with appendicular osteosarcoma.
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Cancer cachexia is a complex syndrome that affectshuman and veterinary patients. In the human med-
ical literature, cancer cachexia has been defined by
international consensus as a loss of skeletal muscle mass
with or without a loss of fat mass and develops as a
consequence of decreased caloric intake and abnormal
metabolism.1 Cancer cachexia is associated with
decreased survival and quality of life in human patients
with advanced cancer.2,3 The prevalence of this syn-
drome in veterinary medicine has not been widely stud-
ied, and as of yet, no definitive diagnostic criteria
effectively assess cancer cachexia in veterinary patients.
One study investigated cancer cachexia characterized
by body condition score (BCS) in 100 dogs at the
time of presentation to a veterinary oncology service.4
In that study, 4% of the dogs had cachexia, defined
as a BCS ≤3 of 9 and 15% percent had moderate-to-
severe muscle wasting.4 The investigators concluded
that BCS alone may not be sensitive enough to detect
cancer cachexia. A similar study of 57 cats that were
treated for various neoplastic conditions reported that
feline cancer patients with BCS <5 had significantly
shorter median survival time compared to cats with
BCS ≥5.5 Similarly, that study also showed a signifi-
cant association between body weight and median
survival time.5
A recent study of dogs assessed the effect of obesity
on survival time in dogs with lymphoma and osteosar-
coma.6 The study did not find that BCS was associated
with survival time in dogs with osteosarcoma, but did
find that underweight dogs with lymphoma had a signif-
icantly shorter survival time than dogs that maintained
or gained weight.6
Weight loss has been shown to be a negative prog-
nostic indicator for response to chemotherapy, surgical
risk and survival time in human cancer patients.3,7 A
retrospective study assessing weight change during
chemotherapy in women with ovarian cancer found that
increasing body weight during therapy was associated
with improved overall survival, whereas weight loss was
associated with poor overall survival.8
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Appendicular osteosarcoma is a relatively common
and aggressive cancer in dogs, accounting for up to
85% of all canine primary bone tumors.9,10 Amputation
and chemotherapy are the standard of care for osteosar-
coma, with single-agent carboplatin being a commonly
used protocol for this disease.11–17 We have noted anec-
dotally that some canine osteosarcoma patients experi-
ence substantial weight loss over the course of
postamputation chemotherapy. However, it is not
known how commonly this occurs, or its potential effect
on prognosis.
The objectives of our study were as follows: (1) to
determine the patterns of weight change in dogs with
appendicular osteosarcoma treated with amputation
and single-agent carboplatin during the course of adju-
vant chemotherapy; (2) and determine whether postop-
erative weight change is a negative prognostic indicator
for survival time in dogs with osteosarcoma. We
hypothesized that canine osteosarcoma patients would
lose weight during the course of carboplatin chemother-
apy and that patients with weight loss would have
decreased survival time compared to those with static
or increased weight during treatment.
Materials and Methods
Ours was a retrospective multi-institutional study. Cases were
accrued from the University of Florida, College of Veterinary
Medicine, the University of California-Davis, School of Veterinary
Medicine, and the University of Guelph, Ontario Veterinary Col-
lege. Inclusion criteria were dogs with histologically confirmed
osteosarcoma that were treated with limb amputation followed
with intent-to-treat of 6 doses of carboplatin, with a minimum of
4 doses administered. Exclusion criteria were patients that under-
went a limb-sparing procedure, received chemotherapy before
amputation, or were treated with combination chemotherapy pro-
tocols during carboplatin treatment. Dogs that received additional
chemotherapeutic agents and bisphosphonates after completing
their carboplatin protocol were included. Data collected from each
patient included signalment, tumor site, preoperative serum alka-
line phosphatase activity (ALP), cytology results if available, pre-
operative diagnostic imaging results (eg, chest radiographs, bone
scan, thoracic computed tomography [CT], whole body CT), pres-
ence or absence of gross metastasis, number of doses of carbo-
platin administered, additional therapies administered, date and
location of metastasis, date of last follow-up, and date and cause
of death. Weight (kg) before amputation and at each chemother-
apy administration was recorded. Patient age was defined as age
(days) at the date of amputation. Survival time was defined as the
date of amputation to the date of death (days). Weight at the time
of the first administration of carboplatin was used as baseline
weight. Weight loss was defined as any weight lower than baseline.
Statistical Analysis
Descriptive statistics (median [range]) for continuous variables;
number [N] and proportion for categorical variables) were used for
summarizing the data. Weight change for each dog was computed
as the difference in weight between the last and first carboplatin
dose that the dog received. Overall survival time, defined as the time
from the date of amputation to the date of death or last follow-up,
was compared between groups by the Log-rank test. The corre-
sponding hazard ratio and its 95% confidence interval were esti-
mated through the Cox proportional hazard regression model.
Results
Eighty-eight dogs met the inclusion criteria. There
were 45 castrated males, 5 intact males, 36 spayed
females, and 2 intact females. The most common breeds
represented were Golden Retrievers (13%), Rottweilers
(13%), Labrador Retrievers (11%), Doberman Pinsch-
ers (8%), mixed breed (8%), Greyhounds (7%), Mas-
tiffs (7%), and Great Danes (6%). All other breeds
represented <4% of study dogs. Pre-amputation body
weight ranged from 21 to 94 kg with a median body
weight of 39.7 kg. The most frequent tumor sites were
distal radius (N = 28), proximal humerus (N = 20), dis-
tal femur (N = 14), proximal tibia (N = 9), and distal
tibia (N = 9). All other sites consisted of ≤4 cases per
site. Thirty-seven dogs received 4 doses of carboplatin,
16 received 5 doses, and 35 received 6 doses. Of 80 dogs
with preoperative ALP activity available, 11 had
increased activity. The overall median survival time for
the dogs was 360 days (range, 289–461). Institution
(P = .7626), patient sex (P = .3283), age (P = .1788),
body weight at dose 1 (P = .1334), number of doses of
carboplatin (P = .1593), and ALP activity (P = .5991)
did not have a significant effect on survival.
Of the 88 dogs in our study, 36 lost weight during
treatment, 3 had stable weight, and 49 gained weight.
The mean percentage weight changes from dose 1–4,
1–5, and 1–6 were 1.5, 2.2, and 0.3%, respectively, indi-
cating a slight increase in weight (Fig 1). Overall,
weight did not vary significantly during the course of
carboplatin treatment. Weight change did not have a
significant effect on survival (P = .1044).
Discussion
Signalment, body weight, tumor site, and median sur-
vival time were consistent with previous reports of dogs
with appendicular osteosarcoma.9,11–14,16,18 Of the dogs
Fig 1. Weight change (%) at carboplatin doses 4, 5, and 6, relative
to dose 1. Weight change (%) was evaluated between doses 4, 5, and
6 of carboplatin relative to dose 1. The solid line represents dose 4
relative to dose 1 (37 dogs), the small dashed line represents dose 5
relative to dose 1 (16 dogs), and the large dashed line represents dose
6 relative to dose 1 (35 dogs).
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with available preoperative ALP activity, 14% had
increased activity, and increased ALP activity did not
have a significant prognostic effect. This result differs
from previous studies, in which increased ALP activity
was a negative prognostic factor.18,19 This finding may
be due to type II error because of the low number of
dogs in our study with increased ALP activity.
Our first aim was to characterize the weight change
that occurred during standard of care treatment of
osteosarcoma in dogs. Although weight change was not a
significant prognostic indicator of survival, we did notice
an overall slight increase in body weight in 56% of dogs
during treatment. However, this change was not statisti-
cally significant, indicating that, for this population of
dogs, weight generally was stable or increased slightly
during chemotherapy. This finding may be attributable
to decreased physical activity after amputation, lack of
client instruction to decrease caloric intake with
decreased activity or both. The slight weight gain also
may have been a consequence of owners giving their dogs
more food to treat them due to the fact that they had can-
cer. These data caused us to reject our first hypothesis
that dogs would lose weight during the course of therapy.
We did not have enough dogs that experienced
weight loss in our study to assess whether or not weight
loss was a negative prognostic indicator. Therefore, we
rejected our second hypothesis that weight loss would
be a negative prognostic indicator for survival for
affected dogs. In fact, overall, weight loss was not a
characteristic of this population of dogs. Cancer
cachexia may be uncommon in dogs with osteosarcoma,
and a study of a larger group of affected dogs would be
necessary to determine whether weight loss is a factor
in prognosis. Weight loss alone also may be an insensi-
tive variable to assess cancer cachexia. Limitations of
our study included lack of available body and muscle
condition scores, appetite history, and diet history.
Loss of lean body mass is the defining characteristic
of cachexia, and therefore, other factors such body con-
dition in conjunction with muscle condition also should
be taken into account.1,20 Body condition scoring
assesses adipose tissue, and at normal and overweight
body conditions, it can be difficult to evaluate muscle
wasting.21–23 For this reason, we recommend that future
studies use consistent methods and scales of assessing
body condition as well as muscle condition to more
appropriately assess cachexia.21–24
More recent studies in veterinary and human medi-
cine have aimed to assess lean body mass using dual
energy X-ray absorptiometry and CT and ultrasound
measurements of epaxial musculature.1,25,26 Dual energy
X-ray absorptiometry is used to assess body composi-
tion, and CT and ultrasound measurements compare
cross-sectional or transverse views, respectively, of the
epaxial musculature in dogs. In 1 study, epaxial muscle
area was significantly lower in older, sarcopenic animals
compared to younger animals.26 Additional studies are
needed to assess the accuracy and limitations of these
methods in animals.
In conclusion, dogs with appendicular osteosarcoma in
our study treated with amputation and adjunctive
carboplatin therapy did not experience significant weight
loss and actually experienced slight weight gain during
treatment. Weight change was not prognostic in this
group of dogs, and weight loss alone may not be a suit-
able method of determining cancer cachexia in dogs with
appendicular osteosarcoma. Additional studies assessing
weight change, BCS, and muscle mass, as well as incorpo-
ration of physiotherapy and nutritional management of
veterinary patients, are needed to assess the effects of
nutrition and changes in metabolism associated with can-
cer on prognosis.
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